During the 2024 International Biomedical Industry Innovation Conference Beijing Forum, six multinational pharmaceutical companies - Lilly, Pfizer, Bayer, AstraZeneca, Medtronic, and HUYABIO - chose to establish their R&D innovation institutions in the BioPark of the Beijing Economic-Technological Development Area (Beijing E-Town).

Currently, Beijing E-Town is accelerating the planning and construction of its BioPark, aiming to concentrate high-level innovation resources, support high-value innovative products, create an efficient innovation ecosystem, and build a leading area for international pharmaceutical innovation resources. The BioPark has become the "preferred location" for many multinational pharmaceutical companies to deepen their business layout in China.

The R&D innovation institutions that will be established in the BioPark by the six multinational enterprises this time are either their "first in Beijing" or "first in China".

The China Medical Innovation Center of Lilly will support its global drug R&D and registration review, focusing on such diseases as Alzheimer's, diabetes, and weight loss, accelerating the development of breakthroughs in innovative treatments. In addition, it will also establish in Beijing its first innovative incubator outside the United States.

As its first entity in Beijing, the new R&D center of Pfizer will be dedicated to conducting international multi-center clinical trials and promoting the global synchronization of clinical trials, especially in developing new products in the field of oncology.

As a leading enterprise in the international medical device field, Medtronic will establish its first digital service innovation base in the BioPark, which will be dedicated to developing cardiovascular disease treatment solutions based on artificial intelligence and big data.

HUYABIO will establish its China headquarters in the BioPark, becoming the first international platform in the city to focus on innovative drug exports.

AstraZeneca will establish its new Global R&D Beijing Center, serving as AstraZeneca's only rare disease drug research institution in China.

Bayer will set up its first open innovation center in China, continuously introducing innovative drugs in the fields of cardiovascular diseases, oncology, as well as promote innovative solutions in women's health and ophthalmic diseases.

Biotechnology and the health industry are one of the four leading industries in Beijing E-Town. Currently, Beijing E-Town has attracted 159 projects invested by 104 Fortune 500 companies, with a scale of nearly 100 billion yuan ($14.03 billion) in the pharmaceutical and health industry. It has gathered nearly 5,000 companies in various fields including biopharmaceuticals, medical devices, biotechnology, and medical materials.